GlassScriptPhysician profile
John W Cochran
NPI 1811989957
$53,749.90
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $12K · 2021: $2,061 · 2022: $252.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40,977.90 | 2019-2020 | |
| Eisai INC. | $9,540.00 | 2020-2021 | |
| Ucb, INC. | $540.21 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $416.23 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $270.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $240.27 | 2019-2020 | |
| Lilly USA, LLC | $230.75 | 2019 | |
| Sunovion Pharmaceuticals INC. | $200.35 | 2019-2020 | |
| Genzyme Corporation | $186.27 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $176.34 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $155.77 | 2019 | |
| Allergan, INC. | $152.13 | 2019-2020 | |
| Biogen, INC. | $115.08 | 2019-2020 | |
| Ceribell, INC. | $106.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $60.22 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $56.78 | 2019-2020 | |
| Acorda Therapeutics, INC | $55.22 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $46.05 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $42.38 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $41.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $27.40 | 2020 | |
| Acadia Pharmaceuticals INC | $25.19 | 2022 | |
| Harmony Biosciences LLC | $20.66 | 2020 | |
| Fisher & Paykel Healthcare INC | $18.86 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.33 | 2019 | |
| Travere Therapeutics, INC. | $16.15 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.